Compositions and methods comprising medium chain triglycerides for treatment of epilepsy

US10668041B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10668041-B2
Application numberUS-201715690520-A
CountryUS
Kind codeB2
Filing dateAug 30, 2017
Priority dateDec 8, 2014
Publication dateJun 2, 2020
Grant dateJun 2, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a method for treating epilepsy in a companion animal can comprise administering to the companion animal a food composition comprising a medium chain triglyceride (MCT), wherein the MCT is present in the food composition in an effective amount for reducing or preventing seizures when the food composition is administered to the companion animal.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for treating epilepsy in a companion animal comprising administering to the companion animal a food composition comprising a medium chain triglyceride (MCT) about 15% to about 50% protein, wherein the MCT is present in the food composition from about 1% to about 7% by weight and is effective for reducing seizures when the food composition is administered to the companion animal, wherein the MCT is of a formula (Formula 1): wherein the R′, R″, and R″′ esterified to the glycerol backbone are each independent fatty acids having 5-12 carbons. 2. The method of claim 1 , wherein the animal is a canine. 3. The method of claim 1 , wherein the animal is a feline. 4. The method of claim 1 , wherein the food composition comprises a nitric oxide releasing compound (NORC). 5. The method of claim 4 , wherein the NORC is arginine. 6. The method of claim 1 , wherein greater than about 95% of the R′, R″, and R″′ are 8 carbons in length. 7. The method of claim 1 , wherein the remaining R′, R″, and R″′ are 6-carbon or 10-carbon fatty acids. 8. The method of claim 1 , further comprising administering an anti-epileptic drug (AED) to the companion animal, wherein the AED is selected from the group consisting of acetazolamide, carbamazepine, chlorazepate, clobazam, clonazepam, diazepam, eslicarbazepine acetate, ethisyxunudem, ethosuximide, felbamate, gabapentin, imepitoin, keppra, lacosamide, lamotrigine, levetiracetam, methylphenobarbitone, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, potassium bromide, pregabalin, primidone, retigabine, rufinamide, sodium bromide, sodium valproate, stiripentol, sulthiame, tiagabine, topiramate, valporic acid, vigabatrin, zonisamide, salts thereof, derivatives thereof, and mixtures thereof. 9. The method of claim 1 , wherein the food composition is formulated as a pet food composition or a dietary supplement. 10. The method of claim 1 , wherein the food composition further comprises, about 5% to about 40% fat, about 5% to about 10% ash content, and having a moisture content of about 5% to about 20%. 11. The method of claim 1 , wherein the food composition includes an AED, wherein the AED is selected from the group consisting of acetazolamide, carbamazepine, chlorazepate, clobazam, clonazepam, diazepam, eslicarbazepine acetate, ethisyxunudem, ethosuximide, felbamate, gabapentin, imepitoin, keppra, lacosamide, lamotrigine, levetiracetam, methylphenobarbitone, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, potassium bromide, pregabalin, primidone, retigabine, rufinamide, sodium bromide, sodium valproate, stiripentol, sulthiame, tiagabine, topiramate, valporic acid, vigabatrin, zonisamide, salts thereof, derivatives thereof, and mixtures thereof. 12. The method of claim 1 , wherein the food composition is administered on a regular basis. 13. The method of claim 1 , wherein the food composition is administered on a regular basis for a period of at least one month.

Assignees

Inventors

Classifications

  • Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital · CPC title

  • A61K31/23Primary

    of acids having a carboxyl group bound to a chain of seven or more carbon atoms · CPC title

  • Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title

  • Semi-moist feed · CPC title

  • Moist feed · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10668041B2 cover?
The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a method for treating epilepsy in a companion animal can comprise administering to the companion animal a food composition comprising a medium chain triglyceride (MCT), wherein the MCT is present in the food composition in an effective amount for reducing or preventing seizures when the fo…
Who is the assignee on this patent?
Nestle Sa
What technology area does this patent fall under?
Primary CPC classification A61K31/23. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).